Entering text into the input field will update the search result below

Genome Editing Market Recent Development And Business Trends

Jul. 30, 2020 12:18 PM ET
Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.


  • Genome Editing Market growth factors.
  • Recent Developments in the market.
  • Top Segments.

Market growth influenced due to following factors-

  • Rising government funding and growth in the number of genomics projects.
  • Increasing production of genetically modified crops.
  • High prevalence of infectious diseases and cancer, technological advancements.
  • Growing application areas of genomics.

Global market size-

According to research report the global genome editing market is projected to reach $6.28 billion by 2022, at a CAGR of 14.5%.

Recent Developments-

> In 2019, Thermo Fisher Scientific acquired Brammer Bio to access Brammer Bio’s expertise in manufacturing vectors for genes and cell therapies> In 2019, Horizon Discovery launched predesigned synthetic single-guide RNA (sgRNA) to aid researchers in achieving targeted gene knockouts and conducting DNA-gene free editing> In 2020, New England Biolabs collaborated with ERS Genomics to develop and commercialize CRISPR gene editing tools and reagents

For Details, Download PDF Brochure Here

Top Segment –

•Based on technology, the genome editing market is segmented into CRISPR, TALEN, ZFN, antisense, and other technologies (PiggyBac, Flp-In, Adenine Base Editor (ADE), and Jump-In). The CRISPR segment is expected to register the highest growth during the forecast period.

•Based on end user, the global genome engineering market is segmented into biotechnology & pharmaceutical companies, academic & government research institutes, and contract research organizations.

•The global genome editing market, by application, is segmented into cell line engineering, genetic engineering, and other applications (diagnostics and therapeutics). The cell line engineering segment is estimated to register the highest growth rate during the forecast period.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.